Explore WARF Inventions and Patents
WARF Technologies
WARF’s portfolio of more than 1,500 patented technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.
Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.
Portfolios
New Inventions
Crystallized Vitamin D Analog “SAG-2”
UW–Madison researchers now have developed a method using a mixture of 2-propanol and hexane to crystallize SAG-2. Also, certain diol precursors formed during synthesis may be obtained in crystalline form using ethyl acetate as the solvent. This efficient process removes most of the contaminants from the synthetic SAG-2, resulting in a highly pure product.
P120096US02
Crystallized Vitamin D Analogs “MET-1” and “MET-2”
UW–Madison researchers now have developed a method using either diethyl ether or a mixture of 2-propanol and hexane to crystallize MET-1 and MET-2. This efficient process removes most of the contaminants from the synthetic forms, resulting in a highly pure product.
P120098US02
Crystallized Vitamin D Analog “24F2-DM”
UW–Madison researchers now have developed a method using a mixture of 2-propanol and hexane to crystallize 24F2-DM. This efficient process removes most of the contaminants from the synthetic 24F2-DM, resulting in a highly pure product.
P120313US02
Crystallized Vitamin D Analog “F-24”
UW–Madison researchers now have developed a method using a mixture of 2-propanol and hexane to crystallize F-24. This efficient process removes most of the contaminants from the synthetic F-24, resulting in a highly pure product.
P120342US02
Vitamin D Analog “DA2HE” to Treat and Prevent Polyps, Hyperplastic Intestinal Disorders
UW–Madison researchers have developed a vitamin D analog, seco-A-2,19-dinor-1,25-dihydroxyvitamin D3. Known as DA2HE, the compound exhibits high activity in vivo, especially in intestinal tissues. Relatively low receptor binding, differentiation and transcription activities suggest strong cell selectivity for use against polyps, some cancers and intestinal disorders. The compound’s high intestinal calcium transport activity may be useful against bone diseases.
P120347US02
New Patents
Modular Peptide Binds to Biomaterials and Promotes New Bone Formation
UW–Madison researchers have developed a novel approach for linking growth factors to the surface of an HA-coated biomaterial. Their approach uses a modular peptide design with two functional units: a biologically active growth factor portion that can initiate osteogenesis, angiogenesis or osteogenic differentiation and a binding portion that improves the non-covalent binding of the peptide to “bone-like” HA-based biomaterials. These modular peptides can be used to coat, or “decorate,” biomaterials, providing an improved method of delivering growth factors to skeletal defects.
P09202US
Crystallized Vitamin D Analog 2-Methylene-18,19-Dinor-1Alpha-Hydroxy-Homopregnacalciferol
UW–Madison researchers now have developed a method using precipitation with hexane from ethyl acetate. This efficient process removes most of the contaminants, resulting in a highly pure product. Crystals acceptable for X-ray experiment also can be obtained using hexane from benzene via diffusion exchange.
P100349US02
Novel Antimicrobial Compounds
UW-Madison researchers have developed a method for identifying potential antibiotic compounds that block the association of bacterial SSB with a target protein. The inventors determined—for the first time—the high-resolution structure of the E. coli SSB segment bound to Exonuclease I, a target protein. They used this structure to develop a rapid fluorescence polarization method for measuring SSB-Exonuclease I binding in solution. This method was then used to identify small molecules that inhibit the interaction between bacterial SSB and its target proteins.
Because of the importance of protein interactions with SSB for bacterial viability and the high conservation of the SSB protein binding sequence across bacterial species, these molecules have potent broad spectrum antibacterial properties. Because the SSB peptide sequence is not found in human and other eukaryotic SSBs, these small molecules are also likely to be non-toxic to human cell lines. Together, these features make these compounds excellent candidates for novel, broad spectrum antibiotics.
P07106US
Because of the importance of protein interactions with SSB for bacterial viability and the high conservation of the SSB protein binding sequence across bacterial species, these molecules have potent broad spectrum antibacterial properties. Because the SSB peptide sequence is not found in human and other eukaryotic SSBs, these small molecules are also likely to be non-toxic to human cell lines. Together, these features make these compounds excellent candidates for novel, broad spectrum antibiotics.
